This study tackled the critical public health threat of counterfeit
drugs in Nigeria’s pharmaceutical industry. Deceptive medicines,
containing incorrect or harmful ingredients, are difficult to identify
and have a significant impact on low- and middle-income countries, where
estimates suggest over 10% of medicines are fake. To combat this issue,
a CNN Hybrid model was developed to analyze a self-captured dataset of
medicine packages in the form of images and National Agency for Food and
Drug Administration Control (NAFDAC) numbers. Only 10 of Nigeria’s
registered pharmaceutical brands were taken into consideration due to
the availability of products. Few samples of counterfeit drugs were
obtained from NAFDAC. Other samples were constructed using adapted
techniques from existing studies; this was achieved by modifying the
original graphics slightly to create the counterfeit logos. The proposed
model leveraged pre-trained deep learning architectures, ResNet-50 and
VGG16 (V16RN-50), to extract features from the images that were used for
classification. The extracted features were concatenated and fed into
the custom trainable dense and output layer designed to identify
counterfeit and real medicines. The model achieved an impressive result
in multi-classification with a training accuracy of 95.83%, a
validation accuracy of 94.82%, and a test accuracy of 95.1%.
Counterfeit medicine detection also yielded an excellent training
accuracy of 98.8%, a validation accuracy of 98.1%, and a test accuracy
of 97.3%. The findings were further strengthened by high precision,
recall, and F1-score metrics of 0.951, 0.951, and 0.951 for brand
recognition and 0.973, 0.973, and 0.973 for detection of counterfeit
medicines respectively. Additionally, the model outperformed the
benchmark studies in counterfeit detection. The research demonstrated
the potential of the proposed models to detect counterfeit drugs and
contribute to improved public health in Nigeria
.